Ocular Therapeutics Inc.
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ocular Therapeutics Inc.
Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Ocular’s Dry Eye Drug Fails In Phase II, But It Isn’t Giving Up Yet
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ocular Therapeutics Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice